Research Library
GLP-2 TIRZ research
6 articles to explore, with links to 9 original sources.
About GLP-2 TIRZ
TIRZ is the catalog name for tirzepatide, a peptide investigated at GIP and GLP-1 receptors.
Understand the science
Which two receptors recognize tirzepatide?
Tirzepatide is designed to activate the receptors for glucose-dependent insulinotropic polypeptide, called GIP, and glucagon-like peptide-1, called GLP-1. The “GLP-2” part of the catalog label refers to the label alone.
1 source (2022)
Explore study findings
What a 2026 analysis found across sleep apnea subgroups
Tirzepatide is a modified peptide that activates the GIP and GLP-1 receptors. “GLP-2 TIRZ” is the catalog label. Tirzepatide’s tested targets are GIP and GLP-1, distinct from the GLP-2 receptor. A 2026 analysis asked how sleep apnea outcomes varied with participants’ starting characteristics.
3 sources (2022–2026)
What a head-to-head trial taught researchers about glucose categories
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. It appears under “GLP-2 TIRZ” in the catalog, a name distinct from its receptor targets.
3 sources (2022–2026)
Check methods and identity
What an antibody add-on study measured besides weight
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. The “GLP-2” wording in the catalog label does not correspond to a receptor target.
2 sources (2022, 2026)
How SURMOUNT-MAINTAIN tested weight maintenance
Tirzepatide activates GIP and GLP-1 receptors. In “GLP-2 TIRZ,” the GLP-2 wording is a catalog identifier. The SURMOUNT-MAINTAIN trial examined what happened to body weight after adults had already taken tirzepatide during an initial weight-loss phase.
2 sources (2022, 2026)
Interpret the evidence
Why the heart outcomes trial used an active comparator
Tirzepatide activates GIP and GLP-1 receptors. The catalog wording “GLP-2 TIRZ” refers to tirzepatide and does not identify a GLP-2 target.
3 sources (2022–2026)
